Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial
Sep 24, 2025, 8:49 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The failure of a late-stage trial can severely impact investor confidence, similar to past biotech sell-offs like those of AVXL in 2021 after trial failures, which saw stocks plummet over 50%. Furthermore, HRMY might struggle to recover without strong pipeline candidates.
AI summary
What happened, with direct paths to the underlying reporting
HRMY's experimental drug for a rare disorder failed late-stage trial. Shares dropped 8% post-announcement, indicating market concern.
HRMY's experimental drug for a rare disorder failed late-stage trial.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
HRMY received FDA's Refusal to File for pitolisant in IH. 2025 revenue guidance of $820-$860 million remains intact. Phase 3 trial for Pitolisant HD is planned for Q4 2025. Wakix…
UBS initiated coverage on Harmony with a Buy rating and $56 price target. Wakix sales reached $172.8 million in Q2 2024, growing 29% year-over-year. The patient count on Wakix inc…
